Strides Pharma receives USFDA approval for Colchicine Tablets

11 Mar 2022 , 12:46 PM

Strides Pharma Science Limited on Friday has announced that its step-down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for Colchicine Tablets USP, 0.6 mg from the United States Food & Drug Administration (USFDA).

The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Colcrys® Tablets, 0.6 mg, of Takeda Pharmaceuticals U.S.A., Inc. (Takeda).

According to IQVIA MAT January 2022 data, the US market for Colchicine Tablets USP, 0.6 mg is approximately ~US$ 85 Mn. The product will be manufactured at the company’s facility at Bengaluru and will be marketed by Strides Pharma Inc. in the US market.

Further, the company has 271 cumulative ANDA filings with USFDA of which 245 ANDAs have been approved and 26 are pending approval, said company in a regulatory filing.

At around 12:47 PM, Strides Pharma Science was trading at Rs330.80 apiece up by Rs1.3 or 0.39% on the BSE.